Apollomics (APLM) Other Non-Current Liabilities (2023 - 2025)

Apollomics (APLM) reported Other Non-Current Liabilities of $124000.0 for Q4 2025, down 62.42% quarter-over-quarter from $330000.0 in Q4 2023.

Apollomics (APLM) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends

Apollomics (APLM) has 2 years of Other Non-Current Liabilities data on file, last reported at $124000.0 in Q4 2025.

Other Non-Current Liabilities for Q4 2025 came in at $124000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $124000.0 (changed N/A YoY), and the FY2025 annual result was $124000.0, up 21.57% from the prior year.
Other Non-Current Liabilities retreated to $124000.0 in Q4 2025 per APLM's latest filing, from $330000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $1.3 million in Q2 2023 and troughed at $124000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Apollomics	294.00 Mn	294.00 Mn	-

Download Data